|  | Patient-Centric Dose Design Read this article summarizing the latest developments in orally disintegrating tablets. It highlights Catalent’s Zydis ODT, which powers ~35 products formulations on the market in over 60 countries. Download today! |
Featured Story | By Nick Paul Taylor The pairing of a subcutaneous prime shot with two oral boosters protected nonhuman primates against the coronavirus, setting Patrick Soon-Shiong’s ImmunityBio up to expand its clinical development program. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Xeris Pharmaceuticals has taken a big step toward receiving approval for its ready-to-use formulation of glucagon in the EU. The injectable formulation, branded Ogluo, received a positive opinion from the European Medicines Agency’s drug review committee. read more By Nick Paul Taylor Altimmune has begun a phase 1 clinical trial of its long-acting nonalcoholic steatohepatitis drug ALT-801. The asset, like AstraZeneca’s more advanced cotadutide, is a GLP-1/glucagon receptor dual agonist, but it has a less-frequent dosing schedule and potentially superior tolerability. read more By Nick Paul Taylor Researchers have presented preclinical data on the use of antibody-directed microbubbles to get cytotoxic payloads to tumors. The payload remains encapsulated until an ultrasound pulse bursts the bubbles and triggers the release of the therapeutic. read more By Angus Liu The respiratory airway, as the primary entry point of the novel coronavirus, could be a good target for delivery of drugs that aim to protect people against the disease. An antibody nasal spray designed by Eureka Therapeutics protected mice against the virus for at least 10 hours, even at the lowest concentrations tested. read more By Conor Hale Rani Therapeutics has secured $69 million in new funding to move forward with the manufacturing and clinical testing of its “robotic pill”—a small, swallowable capsule that promises to shepherd more delicate drugs past the stomach before releasing them into the bloodstream. read more By Ben Adams There is a wide range of drug programs that saw the final nail in the coffin in 2020, ranging from autism, dermatitis, and dry eye disease, to respiratory, gastrointestinal, and cancer therapies. Check out their obituaries. read more Resources Sponsored By: Metabolon Learn six ways metabolomics provides greater confidence, higher success rates and complements the work of your in-house teams for your drug development pipeline. Sponsored by: ZS Learn how Aerie fueled their product launches with advanced analytics. Sponsored By: Elligo Health Research® Understanding the Challenges COVID-19 Pediatric Clinical Trials Face | White Paper Sponsored By: Thermo Fisher Scientific Lack of resources to move from lab concept to the manufacture/delivery of GMP clinical supplies to patients, key milestones can be missed. Sponsored by: Covance Download the whitepaper to learn how your safety organization can implement automation technologies to enable process and cost efficiencies, improve resource allocation and ensure compliance and quality. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored By: BBK Worldwide The BBK Worldwide Study Voices 2020 survey gives voice to the healthcare consumer in the wake of COVID-19 and reveals important insights for clinical trial enrollment and engagement. Sponsored By: BioAnalytix Download this eBook and Learn the Advantages of LC-MS based HCP Profiling for Development of Complex Biologics. Sponsored By: Polpharma Biologics Innovative cell lines and early process development are critical to generate a high producing cell lines alongside a USP strategy to meet high quality standards. Sponsored by: Rousselot This infographic describes the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments. Sponsored By: Lonza Liquid-filled hard capsule formulations offer unique options for the manufacture and dosing of highly potent actives. Sponsored by: Aldevron Gene and cell therapy organizations are asked to balance the need for rapid clinical progression and stringent quality expectations throughout development. In this document, Aldevron provides an in-depth look at preparing for plasmid manufacturing based on our years of experience. Sponsored By: Outer Edge Technology A sound Cloud Strategy provides the flexibility and tools businesses need to quickly adapt and operate securely in an ever-changing remote work environment. Learn how your company can cost-effectively empower its employees to be productive and secure while working remotely. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools. Sponsored by: Catalent This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. | 
